NCT05854381View on ClinicalTrials.gov

To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

September 19, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2027

Conditions
HIV I Infection
Interventions
BIOLOGICAL

VIR-1388

VIR-1388 is given by subcutaneous injection

BIOLOGICAL

Placebo

The HT Diluent Placebo is HT buffer (20 mM histidine, 10% trehalose-dihydrate, pH 7.2) and contains no active ingredient and will be administered by subcutaneous injection

Trial Locations (10)

1862

Perinatal HIV Research Unit, Soweto

4092

Chatsworth Clinical Research Site, Overport

4110

Isipingo Clinical Research Site, Isipingo

15213

University of Pittsburgh CRS, Pittsburgh

19104

Penn Prevention CRS, Philadelphia

30030

The Hope Clinic of the Emory Vaccine Center CRS, Decatur

32077

Beth Israel Deconess Medical Center VCRS, Boston

35222

Alabama CRS, Birmingham

98104

Seattle Vaccine and Prevention CRS, Seattle

0152

Setshaba Research Centre CRS, Soshanguve

All Listed Sponsors
collaborator

HIV Vaccine Trials Network

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT05854381 - To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV | Biotech Hunter | Biotech Hunter